Last reviewed · How we verify

Rifampin daily for 16 weeks

Centers for Disease Control and Prevention · Phase 2 active Small molecule

Rifampin daily for 16 weeks is a Small molecule drug developed by Centers for Disease Control and Prevention. It is currently in Phase 2 development.

At a glance

Generic nameRifampin daily for 16 weeks
SponsorCenters for Disease Control and Prevention
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rifampin daily for 16 weeks

What is Rifampin daily for 16 weeks?

Rifampin daily for 16 weeks is a Small molecule drug developed by Centers for Disease Control and Prevention.

Who makes Rifampin daily for 16 weeks?

Rifampin daily for 16 weeks is developed by Centers for Disease Control and Prevention (see full Centers for Disease Control and Prevention pipeline at /company/centers-for-disease-control-and-prevention).

What development phase is Rifampin daily for 16 weeks in?

Rifampin daily for 16 weeks is in Phase 2.

Related